Drug Profile
Research programme: anti-inflammatory therapeutics - TaiwanJ Pharmaceuticals
Alternative Names: JKB-117; JKB-119Latest Information Update: 24 Aug 2023
Price :
$50
*
At a glance
- Originator Jenken Biosciences
- Developer Jenken Biosciences; TaiwanJ Pharmaceuticals
- Class Anti-inflammatories
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Nephritis; Pulmonary fibrosis; Rheumatoid arthritis
Most Recent Events
- 24 Aug 2023 Discontinued - Preclinical for Nephritis in Taiwan (unspecified route)
- 24 Aug 2023 Discontinued - Preclinical for Pulmonary fibrosis in Taiwan (unspecified route)
- 24 Aug 2023 Discontinued - Preclinical for Rheumatoid arthritis in Taiwan (unspecified route)